Aduro Biotech (NASDAQ: ADRO) has recently received a number of price target changes and ratings updates:

  • 8/3/2017 – Aduro Biotech was given a new $18.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Aduro Biotech was given a new $30.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/2/2017 – Aduro Biotech was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/2/2017 – Aduro Biotech was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters.”
  • 7/25/2017 – Aduro Biotech was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/18/2017 – Aduro Biotech is now covered by analysts at Cowen and Company. They set an “outperform” rating on the stock.
  • 7/4/2017 – Aduro Biotech was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, being a development-stage company, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters.”

Aduro Biotech, Inc. (NASDAQ ADRO) opened at 12.25 on Monday. The firm has a 50-day moving average price of $12.14 and a 200 day moving average price of $10.93. Aduro Biotech, Inc. has a 52 week low of $8.75 and a 52 week high of $16.43. The company’s market cap is $902.53 million.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. During the same period in the prior year, the firm posted $0.03 EPS. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. Analysts expect that Aduro Biotech, Inc. will post ($1.33) EPS for the current fiscal year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 5,699 shares of the business’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $9.92, for a total transaction of $56,534.08. Following the completion of the sale, the insider now owns 41,300 shares of the company’s stock, valued at $409,696. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dirk G. Brockstedt sold 8,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The shares were sold at an average price of $9.72, for a total value of $77,760.00. Following the sale, the executive vice president now directly owns 57,300 shares of the company’s stock, valued at approximately $556,956. The disclosure for this sale can be found here. Insiders have sold 419,205 shares of company stock valued at $4,410,591 in the last three months. 6.60% of the stock is currently owned by corporate insiders.

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Receive News & Ratings for Aduro Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.